Evaluation of the long-term safety and efficacy of 311c90 in the treatment of migraine

European Neurology

Volumn 36, Issue , 1996, Pages 24-27

  Geraud, Gilles E A ^a  

^a CHU RANGUEIL   (France)

Author keywords

311C90; Efficacy; Long term administration; Safety

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN AGONIST; ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL CHEMISTRY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ELECTROCARDIOGRAPHY; FEMALE; HEART PALPITATION; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SOMNOLENCE; TACHYCARDIA; TIME; URINALYSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHILD; DRUG ADMINISTRATION SCHEDULE; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0030070179     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119100     Document Type: Article

References (9)

1. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by the novel serotonin (5-HT)-lD agonist 31 1C90. Headache 1994;34:394-399.
2. Martin GR, Dixon RM: Preclinical and eiinical pharmacology of the novel antimigraine compound. 31 1C90. Headache 1995:35:291.
3. Seaber E, On N, Jackson S, Dixon R, Watt H, Posner J: Similar pharmacokinetics and tolera-bility of the novel antimigraine compound 311C90 in young and elderly volunteers. Cephalalgia 1995; 15(suppl 14):216.
4. Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM: A multicenter, double-blind, placebo-controlled study to investigate the efficacy and safety of oral doses of 3I1C90 in the acute treatment of migraine. Headache. 1995:35: 292.
5. Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD: 311C90. a new central and peripherally acting 5-HTID receptor agonist in the acute oral treatment of migraine: a double blind, placebo controlled, dose range finding study. Neurology 1996:46:522-526.
6. Rapoport AM, Cady RK, Matthew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL, Brown DL for the US 311C90 Dose Ranging Study Group: Optimizing the oral dose of 3IIC90 in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):221.
7. Klein KB: 311C90. a new acute treatment for migraine: an efficacy overview. Cephalalgia 1995; 15(suppl 14): 175.
8. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1988;8(suppl 7): 1-96.
9. Earl NL: 31IC90. a new acute treatment for migraine: an overview of safety. Cephalalgia 1995;15(suppl 14):217.